89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals

Current Topics in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 446-457

  Vugts, Danielle J ^a   Visser, Gerard W M ^a   van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biologicals; Immuno PET; Monoclonal antibodies; PET; Positron emission tomography; Proteins; Radiometal; Zirconium 89

Indexed keywords

ABARELIX; AFLIBERCEPT; ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CARFILZOMIB; CETUXIMAB; DEFEROXAMINE; DEGARELIX; DENOSUMAB; FRESOLIMUMAB; GEMTUZUMAB OZOGAMICIN; GOSERELIN; IBRITUMOMAB TIUXETAN; IPILIMUMAB; LEUPRORELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; OFATUMUMAB; PANITUMUMAB; PEGINTERFERON ALPHA2B; PERTUZUMAB; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; YTTRIUM; ZIRCONIUM; DIAGNOSTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; BONE METASTASIS; BREAST METASTASIS; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; COLON METASTASIS; COLORECTAL CANCER; CYCLOTRON; ENZYME LINKED IMMUNOSORBENT ASSAY; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HODGKIN DISEASE; HUMAN; IMMUNOREACTIVITY; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; MELANOMA; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOCHEMISTRY; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; STOMACH CANCER; THIN LAYER CHROMATOGRAPHY; ANIMAL; NEOPLASM; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; ZIRCONIUM;

EID: 84878795886     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313040005     Document Type: Review

References (63)

1. Mellstedt, H.; Niederwieser, D.; Ludwig, H. The challenge of biosimilars. Ann of Oncology, 2008, 19, 411-419.
2. van Dongen, G.A.M.S.; Vosjan, M.J.W.D. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother. Radiopharm., 2010, 25, 375-385.
3. McCabe, K.E.; Wu, A.M. Positive progress in immunoPET-not just a coincidence. Cancer Biother. Radiopharm., 2010, 25, 253-261.
4. Reichert, J.M.; Dhimolea, E. The future of anitbodies as cancer drugs, Drug Discov. Today, 2012, 17, 954-963.
5. Miller, P.W.; Long, N.J.; Vilar, R.; Gee, A.D. Synthesis of 11C, 18F, 15O and 13N radiolabeled for positron emission tomography. Angew. Chem. Int. Ed., 2008, 47, 8998-9033.
6. Nayak, T.; Brechbiel, M.W. Radioimmunoimaging with longerlived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem., 2009, 20, 825-841.
7. Ikotun, F.O.; Lapi, S.E. The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. Future Med.Chem., 2011, 3, 599-621.
8. Wadas, T.J.; Wong, E.H,; Weisman, G.R.; Anderson, C.J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev., 2010, 110, 2858-2902.
9. Zeglis, B.M.; Lewis, J.S. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Trans., 2011, 40, 6168-6195.
10. Kaur, S.; Venktaraman, G.; Jain, M.; Senapati, S.; Garg, P.K.; Batra, S.K. Recent trends in antibody-based oncologic imaging. Cancer Lett., 2012, 315, 97-111.
11. Severin, G.W.; Engle, J.W.; Barnhart, T.E.; Nickles, R.J. 89Zr radiochemistryfor positron emission tomography. Med Chem., 2011, 7, 389-394.
12. Zhang, Y.; Hong, H.; Cai, W. PET tracers based on zirconium-89. Curr. Radiopharm., 2011, 4, 131-139.
13. Verel, I.; Visser, G.W.M.; Boellaard, R; Stigter-van Walsum, M.; Snow, G.B.; van Dongen, G.A.M.S. 89Zr Immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med., 2003, 44, 1271-1281.
14. Verel, I.; Visser, G.W.M.; Boerman, O.C.; van Eerd, J.E.M.; Finn, R.; Boellaard, R.; Vosjan, M.J.W.D.; Stigter-van Walsum, M.; Snow, G.B.; van Dongen, G.A.M.S. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm., 2003, 18, 655-661.
15. Meijs, W.E.; Haisma, H.J.; van der Schors, R.; Wijbrandts, R.; van den Oever, K.; Klok, R.P.; Pinedo, H.M.; Herscheid, J.D.M. A facile method for the labeling of proteins with zirconium isotopes. Nucl. Med. Biol., 1996, 23, 439-448.
16. Kozak, C.M.; Mountford, P. Encyclopedia of inorganic and bioinorganic chemistry, John Wiley & Sons, Ltd.: New York, 2006.
17. Baroncelli, F.; Grossi, G. The complexing power of hydroxamic acids and its effect on the behaviour of organic extractants in the reprocessing of irradiated fuels-I: the complexes between benzohydroxamic acid and zirconium, iron (III) and uranium (VI).J. Inorg. Nucl. Chem., 1965, 27, 1085-1092.
18. Fouché, K.F.; le Roux, H.J.; Phillips, F.; Complex formation of Zr(IV) and Hf(IV) with hydroxamic acids in acidic solutions. J. Inorg. Nucl. Chem., 1970, 32, 1949-1962.
19. Meijs, W.E.; Herscheid, J.D.M.; Haisma, H.J.; Wijbrandts, R.; van Langevelde, F.; Mooy, R.; Pinedo, H.M. Production of highly pure no-carrier added 89Zr for the labeling of antibodies with a positron emitter. Appl. Radiat. Isot., 1994, 45, 1143-1147 and references therein.
20. Holland, J.P.; Sheh, Y.; Lewis, J.S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol., 2009, 36, 729-739.
21. Vosjan, M.J.W.D.; Perk, L.R.; Roovers, R.C.; Visser, G.W.M.; Stigter-van Walsum, M.; van Bergenen Henegouwen, P.M.P.; vanDongen, G.A.M.S. Facile labeling of an anti-epidermal growth factor receptor nanobody with gallium-68 via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging, 2011, 753-763.
22. Busse, S.; Brockmann, J.; Rösch, F. [90gNb]DFO-Succinyl-(D)-Phe1-Octreotide: first radiolabeling experiments of DFO-Succinyl-(D)Phe1-Octreotide (SDZ 216-927) with analogous nocarrieradded 95gNb and investigation of its in vitro stability. J. Labelled Comp. Radiopharm 1999 Suppl. 1, 300-302.
23. Holland, J.P.; Divilov, V.; Bander, N.H.; Smith-Jones, P.M.; Larson, S.M.; Lewis, J.S. 89Zr-DFO-J591 for immunoPET of prostatespecific membrane antigen expression in vivo. J. Nucl. Med., 2010, 51, 1293-1300.
24. Meares, C.F.; McCall, M.J.; Reardan, D.T.; Goodwin, D.A. Diamanti, C.I.; McTique, M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem., 1984, 142, 68-78.
25. Vosjan, M.J.W.D.; Perk, L.R.; Visser, G.W.M.; Budde, M.; Jurek, P.; Kiefer, G.A.; van Dongen, G.A.M.S. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine. Nat. Protoc., 2010, 5, 739-743.
26. Lindmo, T.; Boven, E.; Cuttitta, F.; Fedorko, J.; Bunn, P. A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 1984, 72, 77-89.
27. Meijs W.E.; Haisma, H.J.; Klok, R.P.; van Gog, F.B.; Kievit, E.; Pinedo, H.M.; Herscheid, J.D.M. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J.Nucl. Med., 1997, 38, 112-118.
28. Alley, S.C.; Benjamin, D.R.; Jeffrey, S.C.; Okeley, N.M.; Meyere, D.L.; Sanderson, R.J.; Senter, P.D. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconj. Chem., 2008, 19, 759-765.
29. Verel, I.; Visser, G.W.M.; Boellaard, R.; Boerman, O.C.; van Eerd, J.; Snow, G.B.; Lammertsma, A.A.; van Dongen, G.A.M.S. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J. Nucl. Med., 2003, 44, 1663-1670.
30. Brouwers, A.; Verel, I.; Van Eerd, J.; Visser, G.; Steffens, M.; Oosterwijk, E.; Corstens, F.; Oyen, W.; van Dongen, G.; Boerman, O. PET radioimmunoscintigraphy of renal cell cancer using 89Zrlabeled cG250 monoclonal antibody in nude rats. Cancer Biother. Radiopharm., 2004, 19, 155-163.
31. Perk, L.R.; Visser, G.W.M.; Vosjan, M.J.W.D.; Stigter-van Walsum, M.; Tijink, B.M.; Leemans, C.R.; van Dongen, G.A.M.S. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J. Nucl. Med., 2005, 46, 1898-1906.
32. Perk, L.R; Visser, O.J.; Stigter-van Walsum, M.; Vosjan, M.J.W.D.; Visser, G.W.M.; Zijlstra, J.M.; Huijgens, P.C.; van Dongen, G.A.M.S. Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging., 2006, 33, 1337-1345.
33. Nagengast, W.B.; de Vries, E.G.E.; Hospers, G.A.; Mulder, N.H.; de Jong, J.R.; Hollema, H.; Brouwers, A.H.; van Dongen, G.A.M.S.; Perk, L.R.; Lub-de Hooge, M.N. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med., 2007, 48, 1313-1319.
34. Perk, L.R.; Stigter-van Walsum, M.; Visser, G.W.M.; Kloet, R.W.; Vosjan, M.J.W.D.; Leemans, C.R.; Giaccone, G.; Albano, R.; Comoglio, P.M.; van Dongen, G.A.M.S. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1857-1867.
35. Dijkers, E.C.F.; Kosterink, J.G.W.; Rademaker, A.P.; Perk, L.R.; van Dongen, G.A.M.S.; Bart, J.; de Jong, J.R.; de Vries, E.G.E.; Lub-de Hooge, M.N. Development and characterization of clinicalgrade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J. Nucl. Med., 2009, 50, 974-981.
36. Aerts, H.J.W.L.; Dubois, L.; Perk, L.; Vermaelen, P.; van Dongen, G.A.M.S.; Wouters, B.M.; Lambin, P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med., 2009, 50, 123-131.
37. Oude Munnink, T. H.; de Korte, M.A.; Nagengast, W.B.; Timmer-Bosscha, H.; Schröder, C.P.; de Jong, J.R.; van Dongen, G.A.M.S.; Jensen, M.R.; Quadt, C.; Lub-de Hooge, M.N.; de Vries, E.G.E. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur. J. Cancer, 2010, 46, 678-684.
38. Nagengast, W.B.; de Korte, M.A.; Oude Munnink, T.H.; Timmer-Bosscha, H.; den Dunnen, W.F.; Hollema, H.; de Jong, J.R.; Jensen, M.R.; Quadt, C.; Garcia-Echeverria, C.; van Dongen, G.A.M.S.; Lub-de Hooge, M.N.; Schröder, C.P.; de Vries, E.G.E.; 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J. Nucl. Med.,2010, 51, 761-767.
39. Heskamp, S.; van Laarhoven, H.W.M.; Molkenboer-Kuenen, J.D.M.; Franssen, G.M.; Versleijen-Jonkers, Y.M.H.; Oyen, W.J.G.; van der Graaf, W.T.A.; Boerman O.C. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J. Nucl. Med., 2010, 51, 1565-1572.
40. Hoeben, B.A.W.; Kaanders, J.H.A.M.; Franssen, G.M.; Troost, E.G.C.; Rijken, P.F.J.W.; Oosterwijk, E.; van Dongen, G.A.M.S.; Oyen, W.J.G.; Boerman, O.C.; Bussink, J. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J. Nucl. Med., 2010, 51, 1076-1083.
41. Holland, J.P.; Caldas-Lopes, E.; Divilov, V.; Longo, V.A.; Taldone, T.; Zatorska, D.; Chiosis, G.; Lewis, J.S. Measuring the pharmacodynamic effect of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab. PLoS One, 2010, 5, e8859.
42. Nagengast, W.B.; Lub-de Hooge, M.N.; Oosting, S.F.; den Dunnen, W.F.A.; Warnders, F-J.; Brouwers, A.H.; de Jong, J.R.; Price, P.M.; Hollema, H.; Hospers, G.A.P.; Elsinga, P.H.; Hesselink, J.W.; Gietema, J.A.; de Vries, E.G.E. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res., 2011, 71, 143-153.
43. Oude Munnink, T.H.; Arjaans, M.E.A.; Timmer-Bosscha, H.; Schröder, C.P.; Hesselink, J.W.; Vedelaar, S.R.; Walenkamp, A.M.E.; Reiss, M.; Gregory, R.C.; Lub-de Hooge, M.N.; de Vries, E.G.E. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J. Nucl. Med. 2011, 52, 2001-2008.
44. van Rij, C.M.; Sharkey, R.M.; Goldenberg, D.M.; Frielink, C.; Molkenboer, J.D.M.; Franssen, G.M.; van Weerden, W.M.; Oyen, W.J.G.; Boerman, O.C. Imaging of prostate cancer with immune-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J. Nucl. Med., 2011, 52, 1601-1607.
45. Ruggiero, A.; Holland, J.P.; Hudolin, T.; Shenker, L.; Koulova, A.; Bander, N.H.; Lewis, J.S.; Grim, J. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J. Nucl. Med., 2011, 52, 1608-1615.
46. Ulmert, D.; Evans, M.J.; Holland J.P.; Rice, S.L.; Wongvipat, J.; Pettersson, K.; Abrahamsson, P-A.; Scardino, P.T.; Larson, S.M.; Lilja, H.; Lewis, J.S.; Sawyers, C.L. Imaging androgen receptor signaling with a radiotracer targeting free-prostate specific antigen.Cancer Discovery, 2012, 2, 320-327.
47. Cohen, R.; Stammes, M.A.; de Roos, I.H.C.; Stigter-van Walsum, M.; Visser, G.W.M.; van Dongen, G.A.M.S. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Res. 2011, 1:31.
48. Terwisscha van Scheltinga, A.G.T.; van Dam, G.M.; Nagengast, W.B.; Ntziachristos, V.; Hollema, H.; Herek, J.L.; Schröder, C.P.; Kosterink, J.G.W.; Lub-de Hooge, M.N.; de Vries; E.G.E. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J. Nucl. Med., 2011, 52, 1778-1785.
49. Börjesson P.K.E.; Jauw, Y.W.S.; Boellaard, R.; de Bree, R.; Comans, E.F.I.; Roos, J.C.; Castelijns, J.A.; Vosjan, M.J.W.D.; Kummer, J.A.; Leemans, C.R.; Lammertsma, A.A.; van Dongen, G.A.M.S. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer. Res., 2006, 12, 2133-2140.
50. Börjesson P.K.E.; Jauw, Y.W.S.; de Bree, R.; Roos, J.C.; Castelijns, J.A.; Leemans, C.R.; van Dongen, G.A.M.S.; Boellaard, R. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J. Nucl. Med., 2009, 50, 1828-1836.
51. Dijkers E.C.; Oude Munnink, T.H.; Kosterink, J.G.; Brouwers, A.H.; Jager, P.L.; de Jong, J.R.; van Dongen, G.A.; Schröder, C.P.; Lub-de Hooge, M.N.; de Vries, E.G. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther., 2010, 87, 586-592.
52. Rizvi, S.N.F.; Visser, O.J.; Vosjan, M.J.W.D.; van Lingen, A.; Hoekstra, O.S.; Zijlstra, J.M.; Huijgens, P.C.; van Dongen, G.A.M.S.; Lubberink, M. Biodistribution, radiation dosimetry andscouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 512-520.
53. Heuveling, D.A.; de Bree, R.; Vugts, D.J.; Huisman, M.C.; Giovannoni, L., Hoekstra, O.S.; Leemans, C.R.; Neri, D.; van Dongen, G.A.M.S. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J. Nucl. Med., 2013, accepted.
54. Perk, L.R.; Vosjan, M.J.W.D.; Visser, G.W.M.; Budde, M.; Jurek, P.; Kiefer, G.A.; van Dongen, G.A.M.S. p-Isothiocyanatobenzyldesferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 250-259.
55. Nayak, T.K.; Garmestani, K.; Milenic, D.E.; Brechbiel, M.W. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J. Nucl. Med., 2012, 53, 113-120.
56. Hong, H.; Severin, G.W.; Yang, Y.; Engle, J.W.; Zhang, Y.; Barnhart, T.E.; Liu, G.; Leigh, B.R.; Nickles, R.J.; Cai, W. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 138-148.
57. Natarajan, A.; Habte, F.; Gambhir, S.S. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconj. Chem., 2012, 23,1221-1229.
58. Vosjan, M.J.W.D.; Vercammen, J.; Kolkman, J.A.; Stigter-van Walsum, M.; Revets, H.; van Dongen, G.A.M.S. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol. Cancer Ther., 2012, 11, 1017-1025.
59. Heuveling, D.A.; Visser, G.W.M.; Baclayon, M.; Roos, W.H.; Wuite, G.J.L.; Hoekstra, O.S.; Leemans, C.R., de Bree, R.; van Dongen, G.A.M.S. 89Zr-nanocolloidal albumin-based PET/CT lymphoscintigraphy for sentinel node detection in head and neck cancer: preclinical results. J. Nucl. Med., 2011, 52, 1580-1584.
60. Keliher, E.J.; Yoo, J.; Nahrendorf, M.; Lewis, J.S.; Marinelli, B.; Newton, A.; Pittet, M.J.; Weissleder, R. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconj. Chem., 2011, 22, 2383-2389.
61. Heuveling, D.A.; van Schie, A.; Vugts, D.J.; Hendrikse, N.H.; Yaqub, M.; Hoekstra, O.S.; Karagozoglu, K.H.; Leemans, C.R.; van Dongen, G.A.M.S.; de Bree, R. Pilot study on the feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for sentinel node identification in oral cancer patients. J. Nucl. Med., 2013, accepted.
62. Zeglis, B.M.; Mohindra, P.; Weissmann, G.I.; Divilov, V.; Hilderbrand, S.A.; Weissleder, R.; Lewis, J.S. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder Click chemistry. Bioconj. Chem., 2011, 22, 2048-2059.
63. Tinianow, J.N.; Gill, H.S; Ogasawara, A.; Flores, J.E.; Vanderbilt, A.N.; Luis, E.; Vandlen, R.; Darwish, M.; Junutula, J.R.; Williams, S.-P. Marik, J. Site-specifically 89Zr-labeled monoclonal antibodies for immunoPET. Nucl. Med. Biol., 2010, 37, 289-297.